

HRA meeting

March 21-22, 2023

IBD Therapeutics Incubator

Andrés Hurtado-Lorenzo, Ph.D.

Vice President, Translational Research & IBD Ventures

Today's Presentation

IBD Therapeutics Incubator


*Innovative funding
mechanism for
drug discovery in IBD*



IBD : Inflammatory Bowel Diseases


IBD Ventures

Investments to accelerate development of solutions for IBD patients




IBD Ventures



Investments to accelerate development of solutions for IBD patients



Therapeutics Discovery Continuum




Bridging the gap between the bench & bedside




Specialized Infrastructure Pharmaceutical Scientists Financial Resources

IBD Therapeutics Incubator

Providing resources to accelerate drug discovery – R&D led by Foundation's scientific staff





IBD Therapeutics Incubator

Proof of Concept Study



PAI-1 Target for Drug Discovery

Drug target discovered through the Foundation's Genetics Initiative

Drug Target: PAI-1 (Elevated in IBD)

Mode of Action: Inhibition of PAI-1 leads to mucosal healing

Drug Type: PAI-1 Inhibitor




Dr. Stappenbeck

 Cleveland Clinic

***How to translate these findings into
a therapeutic opportunity for
patients?***

IBD Therapeutics Incubator: PAI-1 Drug Discovery



Challenge

Prior PAI-1 systemic inhibitors have safety liabilities

Goal

Identify potent, safe gut-targeted PAI-1 inhibitors

Outcomes - Efficacious Drug-Like PAI-1 Inhibitor Discovered

Drug-like inhibitor of PAI-1(CCF104) identified

- ✓ Gut restricted
- ✓ Potent
- ✓ Heal gut ulcers (mucosal healing)
- ✓ Improves colitis end points

Ongoing support by the IBD Therapeutics Incubator

- ✓ Identification of PD biomarkers to support future clinical development
- ✓ Presentation to Venture Capital


Follow-on Funding & Spin-off

- ✓ Multi-million follow-on funding raised
- ✓ **New company created**

Successful proof of concept

The Foundation's Therapeutics Incubator effectively accelerates drug discovery for promising therapeutic targets

Milestones



IBD Therapeutics Incubator

RFP Launched - July 20th 2022

- Worldwide outreach
- Seeking new, differentiated and validated drug targets
- Incubator will provide drug discovery & development resources
- Milestone based funding



[IBD Therapeutics Request for Proposals](https://www.crohnscolitisfoundation.org/research/grants-shipships/ibd-therapeutics-incubator-request-proposals)

Foundation's Drug Discovery & Development Expertise



Jennifer Swantek, PhD

Director, IBD Therapeutics Incubator



Russel Wyborski, PhD

Director, IBD Venture Investments



Andrés Hurtado-Lorenzo, PhD

VP, Translational Research & IBD Ventures



60 years of discovery and development experience

IBD THERAPEUTICS INCUBATOR



Translating innovative academic
research into effective
IBD drug discovery &
development

Thank you !

